Long Term Treatment of Patients With Major Depressive Disorder With MK0869 (0869-065)(COMPLETED)

A Double-Blind, Placebo-Controlled, Multicenter Study of the Long-Term Efficacy of MK0869 in the Maintenance of Antidepressant Effect in Patients With Major Depressive Disorder

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00048594

Enrollment

800

Registered

2002-11-05

Start date

2002-01-03

Completion date

2003-12-22

Last updated

2017-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Brief summary

A clinical study to determine the efficacy and safety of an investigational medication (MK0869) in the treatment of depression.

Detailed description

The duration of treatment is 20 months.

Interventions

DRUGaprepitant

DRUGComparator: placebo (unspecified)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Patients with Major Depressive Disorder

Design outcomes

Primary

Measure	Time frame
Total HAMD-17 score </= 10 after 10 weeks of treatment, time to relapse of depression over 6-10 months	after 10 weeks of treatment and over 6-10 months

Secondary

Measure	Time frame
CGI-S score change from Week 10 at Month 6; HAMD-17 total score change from Week 10 at Month 6; an HAMA total score change from week 10 at Month 6.	Week 10 at Month 6

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026